Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study

Figures & data

Table 1 Characteristics of the 25 patients with cancer who received intravenous iron therapy for non-iron-deficiency anemia

Patient	Sex	Age, years	Type of cancer	Treatment
1	Male	65	Hodgkin’s lymphoma	Chemotherapy
2	Female	48	Neuroblastoma	Chemotherapy
3	Female	50	Breast cancer	Chemotherapy
4	Female	41	High grade sarcoma	Chemotherapy
5	Female	72	Non-small cell lung cancer	Chemotherapy
6	Female	57	Breast cancer	Chemotherapy
7	Male	71	Prostate cancer	Chemotherapy
8	Male	62	Leg leiomyosarcoma	Chemotherapy
9	Female	67	Breast cancer	Chemotherapy
10	Female	70	Endometrial adenocarcinoma	Chemotherapy
11	Female	50	Uterine sarcoma	Chemotherapy
12	Male	56	Bladder cancer	Chemotherapy
13	Male	77	Colon cancer	Chemotherapy
14	Female	27	Neuroendocrine tumor	Chemotherapy
15	Female	33	Osteosarcoma	Chemotherapy
16	Female	61	Breast cancer	Chemotherapy
17	Female	44	Ewing sarcoma	Chemotherapy
18	Male	54	Renal cell carcinoma	Sunitinib and radiotherapy
19	Female	66	Uterine leiomyosarcoma	Chemotherapy
20	Female	55	Breast cancer	Chemotherapy
21	Female	53	Gastric cancer	Chemotherapy
22	Male	66	Rectal cancer	Chemotherapy and radiotherapy
23	Female	69	Breast cancer	Chemotherapy
24	Male	51	Desmoplastic round cell	Chemotherapy
25	Female	31	Breast cancer	Chemotherapy

Table 2 Means and medians of hemoglobin levels (g/dL) of the 25 patients with cancer

	Patients, n	Mean g/dL (SD)	Median g/dL (minimum, maximum)
Baseline (week 1)	25	9.6 (1.06)	9.9 (6.90,10.9)
Week 3	19	10.5 (1.28)	10.7 (6.80,12.1)
Week 6	15	10.5 (1.12)	10.5 (9.10,12.0)
Week 9	15	11.3 (1.37)	11.55 (8.90,13.2)
Week 12	14	11.7 (1.22)	11.35 (9.80,13.7)

Abbreviations: n, number; SD, standard deviation.

Figure 1 Hemoglobin (Hb) level changes for the 14 patients who completed 12 iron infusions (dotted lines) and their mean hemoglobin level change (solid line).